196 related articles for article (PubMed ID: 28740382)
21. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
[TBL] [Abstract][Full Text] [Related]
22. Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.
Sia ZR; Chiem K; Huang WC; Seffouh A; Teimouri Dereshgi A; Hogan T; Ortega J; Davidson BA; Martinez-Sobrido L; Lovell JF
J Virol; 2022 Oct; 96(19):e0100622. PubMed ID: 36106872
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
24. Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice.
Ren Z; Zhao Y; Liu J; Ji X; Meng L; Wang T; Sun W; Zhang K; Sang X; Yu Z; Li Y; Feng N; Wang H; Yang S; Yang Z; Wang Z; Gao Y; Xia X
Vaccine; 2018 Sep; 36(40):5990-5998. PubMed ID: 30172635
[TBL] [Abstract][Full Text] [Related]
25. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
[TBL] [Abstract][Full Text] [Related]
26. A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge.
Sia ZR; He X; Zhang A; Ang JC; Shao S; Seffouh A; Huang WC; D'Agostino MR; Teimouri Dereshgi A; Suryaprakash S; Ortega J; Andersen H; Miller MS; Davidson BA; Lovell JF
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050027
[TBL] [Abstract][Full Text] [Related]
27. HA1-2-fljB Vaccine Induces Immune Responses against Pandemic Swine-Origin H1N1 Influenza Virus in Mice.
Kang X; Yang Y; Jiao Y; Song H; Song L; Xiong D; Wu L; Pan Z; Jiao X
J Mol Microbiol Biotechnol; 2016; 26(6):422-432. PubMed ID: 27721310
[TBL] [Abstract][Full Text] [Related]
28. Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study.
Rungrojcharoenkit K; Sunintaboon P; Ellison D; Macareo L; Midoeng P; Chaisuwirat P; Fernandez S; Ubol S
PLoS One; 2020; 15(8):e0237218. PubMed ID: 32760143
[TBL] [Abstract][Full Text] [Related]
29. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers.
Cohen AA; Yang Z; Gnanapragasam PNP; Ou S; Dam KA; Wang H; Bjorkman PJ
PLoS One; 2021; 16(3):e0247963. PubMed ID: 33661993
[TBL] [Abstract][Full Text] [Related]
30. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
31. Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine.
Quan Le M; Ye L; Bernasconi V; Carpentier R; Fasquelle F; Lycke N; Staeheli P; Betbeder D
Int J Pharm; 2020 May; 582():119348. PubMed ID: 32325240
[TBL] [Abstract][Full Text] [Related]
32. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
[TBL] [Abstract][Full Text] [Related]
33. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
[TBL] [Abstract][Full Text] [Related]
34. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.
Mooney AJ; Li Z; Gabbard JD; He B; Tompkins SM
J Virol; 2013 Jan; 87(1):363-71. PubMed ID: 23077318
[TBL] [Abstract][Full Text] [Related]
35. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
[TBL] [Abstract][Full Text] [Related]
36. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
[TBL] [Abstract][Full Text] [Related]
37. Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
Schmitt S; Tahk S; Lohner A; Hänel G; Maiser A; Hauke M; Patel L; Rothe M; Josenhans C; Leonhardt H; Griffioen M; Deiser K; Fenn NC; Hopfner KP; Subklewe M
Front Immunol; 2020; 11():602802. PubMed ID: 33281829
[TBL] [Abstract][Full Text] [Related]
38. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
[TBL] [Abstract][Full Text] [Related]
39. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
40. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
